|
|
|
| Clinical analysis of thyroid diseases in patients with systemic lupus erythematosus |
| YIN Xietian1,2,3 ZHAO Shichao4 XIANG Nan1,3 ZHOU Guangwen3,5 ZENG Mingxing3,6 |
1.The First Clinical College, Hubei University of Chinese Medicine, Hubei Province, Wuhan 430061, China;
2.Department of Rheumatism Immunology, Hubei Provincial Hospital of Traditional Chinese Medicine, Hubei Province, Wuhan 430061, China;
3.Xiangnan Famous Medical Studio, Hubei Province, Wuhan 430061, China;
4.Department of Geriatrics, Hubei Provincial Hospital of Traditional Chinese Medicine, Hubei Province, Wuhan 430061, China;
5.College of Acupuncture and Orthopedics, Hubei University of Chinese Medicine, Hubei Province, Wuhan 430061, China;
6.College of Basic Medical, Hubei University of Chinese Medicine, Hubei Province, Wuhan 430061, China |
|
|
|
Abstract Objective To study the prevalence of thyroid disease in patients with systemic lupus erythematosus and associated risk factors of Hashimoto′s thyroiditis and subclinical hypothyroidism in systemic lupus erythematosus, so as to provide evidence for clinical prevention and treatment. Methods Sixty-six patients with systemic lupus erythematosus hospitalized in Hubei Hospital of Traditional Chinese Medicine from May 2017 to May 2019 were selected as the study subjects. Among them, a total of 15 cases with Hashimoto′s thyroiditis were observation group A, 26 cases without Hashimoto′s thyroiditis were control group A; a total of 9 cases with subclinical hypothyroidism were observation group B, a total of 52 cases without subclinical hypothyroidism were control group B. The incidence of thyroid disease in systemic lupus erythematosus was observed, and the general condition (gender, age, course of disease), blood analysis, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), immune function, thyroid function, blood lipid (triacylglycerol [TG], high density lipoprotein cholesterol [HDL-C]), uric acid (UA), ENA antibody spectrum, anti-nuclear antibodies (ANA), albumin level (ALB) and clinical manifestations were statistically processed. Results Except for age, there was no statistically significant difference between group A and control group A patients (P ＞ 0.05). Age was an independent risk factor for systemic lupus erythematosus complicated with Hashimoto′s thyroiditis (OR [95%CI] = 1.064[1.004, 1.128], P ＜ 0.05). Except for immunoglobulin M (IgM) and anti-Ds-DNA antibody positive (Ds-DNA), there was no statistically significant difference between other indicators of group B and control group B (P ＞ 0.05). Anti-Ds-DNA antibody was an independent risk factor for systemic lupus erythematosus complicated with subclinical hypothyroidism (OR [95%CI] = 10.573[1.673, 66.810], P ＜ 0.05). Conclusion The incidence of systemic lupus erythematosus complicated with thyroid disease is high. Hashimoto′s thyroiditis and subclinical hypothyroidism are relatively common thyroid diseases. Age is an independent risk factor for systemic lupus erythematosus complicated with Hashimoto′s thyroiditis. Anti-Ds-DNA antibody is an independent risk factor for systemic lupus erythematosus complicated with subclinical hypothyroidism.
|
|
|
|
|
|
[1] 金玲.中国不同发病年龄段系统性红斑狼疮患者临床表现和免疫学指标的差异性研究[D].合肥：安徽医科大学，2019.
[2] Thiyagarajan S，Saini AMR，Alruwaili J. Helicobacter pylori-induced autoimmune thyroiditis：is the pathogenic link concluded or still a hypothesis?[J]. Rev Med Microbiol，2018，29（2）：64-72.
[3] 魏军平，郑慧娟，魏皤.从亚临床甲状腺功能减退症的早期干预看甲状腺功能减退症的预防策略[J].医学研究杂志，2018，47（9）：1-4.
[4] 高辉，李春，陈丽君，等.系统性红斑狼疮患者伴发甲状腺疾病的患病率及临床分析[J].中华风湿病学杂志，2014， 18（7）：449-454.
[5] Hamza RT，Awwad KS，Temsah KA，et al. R620W polymorphism of protein tyrosine phosphatase PTPN22 in Egyptian children and adolescents with systemic lupus erythematosus：relation to thyroid autoimmunity[J]. Int J Adolesc Med Health，2013，25（2）：143-149.
[6] Yun J，Bae JM，Kim K，et al. Increased risk of thyroid diseases in patients with systemic lupus erythematosus：A nationwide population-based Study in Korea[J]. PLoS One，2017，12（6）：e01790886.
[7] Ong SG，Choy CH. Autoimmune thyroid disease in a cohort of Malaysian SLE patients：frequency，clinical and immunological associations [J]. Lupus，2016，25（1）：67-74.
[8] 杨金玲，刘曙艳.系统性红斑狼疮与自身免疫性甲状腺疾病相关性分析[J].社区医学杂志，2018，16（14）：1166-1168，1172.
[9] Wei S，Yang Z，Xie S，et al. Autoimmune Thyroid Disease in Patients with Systemic Lupus Erythematosus：A 7-year Retrospective Study in China[J]. Am J Med Sci，2018， 356（4）：344-349.
[10] Mena-Vázquez N，Nebro AF，Rúa-Figueroa I，et al. Poly autoimmunity in systemic lupus erythematosus. data from a large spanish cohort：Spanish society of rheumatology registry of patients with systemic lupus erythematosus（Relesser）[J]. Lupus Sci Med，2019，6：A61-A62.
[11] Mabrook A，Abd EMI，Rayan MM. Thyroid dysfunction in systemic lupus erythematosus：Its impact as a cardiovascular risk factor[J]. Ann Rheum Dis，2017，76：1216-1217.
[12] 温大蔚，王吉波，赵磊，等.系统性红斑狼疮并发低T3综合征的影响因素分析[J].现代生物医学进展，2014， 14（5）：826-829.
[13] Quintanilla-Flores DL，Hernandez-Coria MI，Elizondo-Riojas G，et al. Thyroid nodules in Hispanic patients with systemic lupus erythematosus[J]. Lupus，2013，22（14）：1509-1513.
[14] Tamez PHE，Quintanilla-Flores DL，Elizondo-Riojas G，et al. Prevalence of thyroid nodules in Mexican patients with systemic lupus erythematosus[J]. Thyroid，2011，21：A39-A40.
[15] 丁源，王吉波，尉世同，等.系统性红斑狼疮伴甲状腺疾病247例临床分析[J].青岛大学医学院学报，2017，53（4）：488-490.
[16] 任洁，周毅，吴会霞，等.系统性红斑狼疮患者亚临床甲状腺功能减退症与狼疮肾炎的关系[J].广东医学，2014（9）：1387-1389.
[17] 中华中医药医学会.系统性红斑狼疮诊疗指南[J].中国中医药现代远程教育，2011，9（11）：146-148.
[18] Elnady BM，Kamal NM，Shaker RH，et al. Prevalence and clinical significance of nonorgan specific antibodies in patients with autoimmune thyroiditis as predictor markers for rheumatic diseases [J]. Medicine（Baltimore），2016， 95（38）：e4336.
[19] 董建华，陈樱花，陈独群，等.狼疮性肾炎合并自身免疫性甲状腺疾病的临床分析[J].肾脏病与透析肾移植杂志，2016，25（6）：526-532.
[20] 王金晶，肖露露，孙文，等.甲状腺相关抗体与缺血性脑血管病的临床研究进展[J].中国脑血管病杂志，2017， 14（8）：445-448.
[21] 鲍晓，黄向阳.系统性红斑狼疮患者亚临床甲状腺功能减退症发病的影响因素研究[J].西部医学，2015，27（9）：1315-1317. |
|
|
|
